Human breast milk and its impact on inflammatory bowel disease

Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing inflammation of tissues in the digestive tract. The onset and exacerbation of IBD is linked to multiple factors, including genetic and immunological influences, diet, and gut bacteria. Additionally, it is associated with a high risk of cancer. Research shows that the longer a person is breastfed, the lower their risk of developing IBD, highlighting the impact of human breast milk components on intestinal bacteria. Human breast milk contains many bioactive components, such as lactoferrin and milk oligosaccharides, are known to be effective in preventing and treating IBD. Probiotics are defined as live microorganisms that provide beneficial effects on the host by altering the balance of indigenous intestinal bacteria. While probiotics, such as lactic acid bacteria and bifidobacteria, have been clinically applied in IBD treatment, there are currently no reports on the application of human breast milk-derived probiotics for this purpose. We clarified the preventive and therapeutic effects of human breast milk-derived probiotics on IBD, as well as the underlying mechanisms. This review highlights the importance of breastfeeding to prevent IBD, and focuses on the therapeutic effects of human breast milk-derived probiotics in IBD. These bioactive compounds in human breast milk are instrumental in establishing a beneficial gut microbiota and promoting proper immune system maturation during early life.